## AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the present application.

## IN THE CLAIMS:

Claims 1 - 8. (Canceled).

Claim 9. (Currently Amended) An isolated tumor antigen peptide of 8 to 14 amino acids in length that is a fragment of the amino acid sequence of SEQ ID NO:1, and that binds to an HLA antigen and is recognized by cytotoxic T lymphocytes, or a derivative thereof which comprises an amino acid residue at position 2 and/or the C-terminus substituted by another amino acid residue, and which has functionally equivalent properties.

Claim 10. (Currently Amended) The isolated tumor antigen peptide of claim 9 wherein the HLA antigen is HLA-A24, or a derivative thereof which comprises an amino acid residue at position 2 and/or the C-terminus substituted by another amino acid residue, and which has the functionally equivalent properties.

Claim 11. (Currently Amended) The isolated tumor antigen peptide of claim 10, which comprises a sequence selected from an amino acid sequence shown in any one of SEQ ID NOs: 3-18, or a derivative thereof an isolated tumor antigen peptide which comprises a sequence selected from an amino acid sequence shown in any one of SEQ ID NOs: 3-18 wherein the amino acid residue at position 2 is substituted by tyrosine, phenylalanine, methionine, or tryptophan, and/or the C-terminus is substituted by another amino acid residue phenylalanine, leucine, isoleucine, tryptophan, or methionine, and which has the functionally equivalent properties.

4

Claim 12. (Currently Amended) The isolated tumor antigen peptide of claim 11, which comprises a sequence selected from an amino acid sequence shown in any one of SEQ ID NOs: 3-5, or a derivative thereof an isolated tumor antigen peptide which comprises a sequence selected from an amino acid sequence shown in any one of SEQ ID NOs: 3-5 wherein the amino acid residue at position 2 is substituted by tyrosine, phenylalanine, methionine, or tryptophan, and/or the C-terminus is substituted by another amino acid residue phenylalanine, leucine, isoleucine, tryptophan,

Appl. No. 09/857,308

or methionine, and which has the functionally equivalent properties.

Claims 13 - 15. (Canceled).

Claim 16. (Currently Amended) The isolated tumor antigen peptide derivative of claim 12, which comprises a sequence selected from an amino acid sequence shown in any one of SEQ ID NOs: 19-21.

Claim 17. (Currently Amended) A pharmaceutical composition for treating tumors, which comprises as an active ingredient at least one of substances selected from the isolated tumor antigen peptides and derivatives thereof according to any one of claims 9 to 12, 15, and 16.

Claim 18. (Canceled).

Claim 19. (Currently Amended) A recombinant polypeptide obtainable by expressing a recombinant DNA comprising at least one of DNAs that encode the tumor antigen peptides or derivatives thereof according to any one of claims 9 to 12, 15, and 16.

Claim 20. A pharmaceutical composition for treating tumors, which comprises as an active ingredient the recombinant polypeptide of claim 19.

Claims 21-27. (Canceled).

٦,

Claim 28. (Currently Amended) A diagnostic agent for tumors, which comprises the tumor antigen peptide or derivative thereof according to any one of claims 9 to 12, 15, and 16, or an isolated protein that is encoded by a DNA of any one of the following (a) to (d):

- (a) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO:1,
- (b) a DNA comprising the nucleotide sequence of SEQ ID NO:2,
- (c) a foreign DNA carried in  $E.\ coli$  JM109 (3D9) (deposit number FERM BP-6929), and
- (d) a DNA which hybridizes with a DNA of any one of (a) to (c) under stringent hybridization conditions wherein said DNA encodes a tumor antigen protein which gives rise to tumor antigen peptide(s) that bind(s) to an HLA antigen and are recognized by cytotoxic T lymphocytes.

Appl. No. 09/857,308

Claim 29. (Previously Presented) A diagnostic agent for tumors, which comprises the recombinant polypeptide of claim 19.